Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(d) On September 27, 2021, the Directors (the "Board") of Arch Therapeutics,
Inc. (the "Company"), increased the size of the Board from three to four
directors and appointed Laurence Hicks as director of the Company, effective
immediately.
Mr. Hicks, age 55, has been the chief executive officer of Healthcare Components
Group, a global manufacturer of OEM and replacement parts used for the
manufacture and repair of medical devices, since 2021. From 2016 until 2021,
when it merged into Healthcare Components Group, Mr. Hicks was chief executive
officer of 2506052 Ontario Inc., a holding company for American Optics,
Endoscopy Replacement Parts and Micro Optics Europe, which sell components used
in the manufacturing and repair of endoscopes worldwide. He has held medical
device leadership roles at ACMI, Karl Storz Endoscopy and NeuroTherm. Mr. Hicks'
experience in the medical device industry was instrumental in his selection as a
member of the Board.
In connection with his appointment to the Board, the Board has granted Mr. Hicks
250,000 stock options, which vest monthly on each of the first 36 month
anniversaries of the grant date and are exercisable at $0.1028 per share. Mr.
Hicks will receive a retainer of $12,500 for his Board service through December
31, 2021. Commencing January 1, 2022, Mr. Hicks will receive an annual retainer
of $25,000 for his service on the Board, an additional $2,500 for any standing
committee of the Board on which he serves as chair, and an additional $5,000 if
Mr. Hicks serves as chair of the Board, up to a maximum of $30,000 per year,
payable in cash or stock.
There are no arrangements or understandings pursuant to which Mr. Hicks was
appointed as a director, and there are no related party transactions between the
Company and Mr. Hicks reportable under Item 404(a) of Regulation S-K.
A copy of the press release announcing Mr. Hicks' appointment to the Board is
filed as Exhibit 99.01 to, and incorporated by reference in, this report.
Item 9.01 Financial Statements and Exhibit
(d) The following exhibits are being filed herewith:
Exhibit Description
99.1 Press Release issued by Arch Therapeutics, Inc. on September 30, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
© Edgar Online, source Glimpses